PAPP ‐A: a promising therapeutic target for healthy longevity | Zendy

Conover Cheryl A. | Zendy; Oxvig Claus | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

PAPP ‐A: a promising therapeutic target for healthy longevity

Author(s) -

Conover Cheryl A.,

Oxvig Claus

Publication year - 2017

Publication title -

aging cell

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.103

H-Index - 140

eISSN - 1474-9726

pISSN - 1474-9718

DOI - 10.1111/acel.12564

Subject(s) - biology , longevity , microbiology and biotechnology , pregnancy associated plasma protein a , receptor , cleavage (geology) , endocrinology , genetics , pregnancy , fetus , paleontology , first trimester , fracture (geology)

Summary Pregnancy‐associated plasma protein‐A ( PAPP ‐A) is a proteolytic enzyme that was discovered to increase local insulin‐like growth factor ( IGF ) availability for receptor activation through cleavage of inhibitory IGF binding proteins ( IGFBP s). Reduced IGF signaling has been associated with increased lifespan and healthspan. Therefore, inhibition of PAPP ‐A represents a novel approach to indirectly decrease the availability of bioactive IGF . Here, we will review data in support of PAPP ‐A as a therapeutic target to promote healthy longevity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research